NCT02577458Unknown1 期
Phase 1 Study of the Combination of CM082 With Everolimus in Patients With Metastatic Renal Cell Carcinoma (RCC): Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
AnewPharma1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.
详细描述
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Renal Cell Carcinoma (RCC). After the maximum tolerated dose (MTD) or the optimal biological dose is identified, an expansion cohort of ~10 advanced renal cell carcinoma patients will be enrolled to further characterize the safety and tumor response by CT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma
- •Progressed on at least one standard therapy
- •Measurable disease per Recist1.1
- •Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1
- •Life expectancy of at least 12 weeks
- •No abnormal bone marrow function
- •Adequate heart, lung, liver, kidney organ system functions, and meet the following requirements:
- •Total bilirubin ≤1.5 times the upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤5x the upper limit of normal with liver involvement.
- •Creatinine ≤ 1.5 x ULN
- •Urine protein <1+
- •QTcF < 450 ms
- •LVEF ≥ 50%
- •At least 4 weeks after receiving cancer therapy (i.e., chemotherapy, radiation therapy, biologic therapy, hormonal therapy); 3 months after surgery and recovered
- •Willingness and ability to comply with trial and follow-up procedures
- •Ability to understand the nature of this trial and give written informed consent
排除标准
- •Currently receiving anti-cancer treatment
- •Other tumors in addition to renal cell carcinoma
- •Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks
- •Concomitant use of drugs with a risk of causing prolonged corrected QT interval and/or Torsades de Pointes
- •Patients with a history of intolerance to, or significant toxicity with VEGFR tyrosine kinase inhibitor(s) (TKI) or everolimus
- •Females who are pregnant or breastfeeding
- •Those in reproductive ages who refuse to use contraception
- •Those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol
- •Patients with known central nervous system (CNS) metastases
- •Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM082 or everolimus
- •Patients with known severe lung disorders such as asthma, chronic obstructive pulmonary disease (COPD)
- •Patients who are HIV positive
- •Drug or alcohol abuser
研究组 & 干预措施
CM082 plus everolimus
Experimental
CM082 plus everolimus
干预措施: CM082 (Drug)
CM082 plus everolimus
Experimental
CM082 plus everolimus
干预措施: Everolimus (Drug)
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 12 months
To determine the Maximum Tolerated Dose of the Combination in Chinese RCC Patients
次要结局
- Pharmacokinetics assessed by area under the plasma concentration versus time curve (AUC) of CM082 and everolimus(12 months)
- Objective response rate(18 months)
- Progress free survival(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaRenal Cell Cancer MetastaticNCT03095040AnewPharma390
Unknown
1 期
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerAdvanced Gastric CancerNCT03286244AnewPharma21
进行中（未招募）
1 期
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsAdvanced Malignant Solid TumorsNCT03792958AnewPharma19
尚未招募
1 期
A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCLiver CancerHCCNCT06584071Biotheus Inc.140
已完成
1 期
Study of EC0225 for the Treatment of Refractory or Metastatic TumorsCancerNCT00441870Endocyte77